Report from Extraordinary General Meeting
On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majority.Approval of the Board of Directors’ decision on a new share issue waiving shareholders’ preferential rightsThe Meeting approved the Board of Directors’ decision on the new issue of a maximum of 2,500,000 shares. Waiving shareholders’ preferential rights, a group of investors, selected in advance, that have notified the company of their interest in subscription, shall be entitled to